Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBA1412 in advanced solid tumors
NCT05501821Phase 1Completed
- Sponsor
- Kling Biotherapeutics
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of kba-1412 in malignant solid tumor (3 arms), sponsored by Kling Biotherapeutics. Primary endpoints: Adverse Events at 1 year, Dose-Limiting Toxicity at 21 days and 1 more. Started Aug 2022; status: completed.
02
Drugs
kba-1412
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05501821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501821.